GP40141 (Ромиплостим)
Проводит ООО «ГЕРОФАРМ»
Страница компанииМногоцентровое простое слепое рандомизированное контролируемое исследование эффективности, безопасности и иммуногенности препарата GP40141 (ГЕРОФАРМ, Россия) в сравнении с препаратом Энплейт® (Амджен, Нидерланды) у пациентов с персистирующей или хронической первичной иммунной тромбоцитопенией.
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/185/2023-04-04/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование идёт.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 160 чел. в стране «Россия».
- Центров в реестре: 12 в 11 городах. Список — ниже на странице.
- Плановое окончание — 03.2028.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 33
Критерии включения
- Signed informed consent to participate in the study.
- male or female
- Age ≥18 years
- Diagnosis of primary immune thrombocytopenia (PIT).
- Duration of PIT at the Screening Visit: for cohort 1: ≥3 months; for cohort 2: ≥6 months.
- PIT therapy with glucocorticosteroids (GCS) for cohort 1: duration of continuous therapy ≥3 months at the Screening Visit or ≥2 courses of pulse therapy during the year before the Screening Visit;
- TPO-RA therapy: for cohort 1: no history of TPO-RA use; for Cohort 2: Use of TPO-RA for ≥12 weeks at the Screening Visit;
- No increase in TPO-RA dose during the 4 weeks preceding the end of screening.
- Blood platelet count: for cohort 1: mean platelet count ≤30×10*9/L, based on the last two measurements 7±2 days apart, each of which had a platelet count ≤35×10*9/L OR steroid dependence, defined as the use of prednisolone at a daily dose of >5 mg (or another corticosteroid at an equivalent dose) for ≥2 months before the Screening Visit to maintain a platelet count ≥30×10*9/L OR to prevent bleeding; for cohort 2: platelet count ≥50×10*9/ml for ≥6 weeks out of the last 8 weeks of follow-up with platelet counts every 7±2 days and no emergency treatment for severe hemorrhagic syndrome in the last 12 weeks before the Screening Visit.
- Consent and ability to comply with the procedures of the Protocol, as well as the prohibitions and restrictions provided for by the Research Protocol.
Критерии невключения
- Hypersensitivity to romiplostim.
- History of TPO-RA use: for cohort 1: any TPO-RA; for cohort 2: any TPO-RA, with the exception of romiplostim and eltrombopag.
- Unpromising treatment with romiplostim in the opinion of the Researcher
- Splenectomy <24 weeks prior to the Screening Visit or planned splenectomy during the study.
- Treatment with rituximab within the 14 weeks preceding the Screening Visit, or planned treatment with rituximab during the study.
- Treatment with intravenous immunoglobulin or anti-D immunoglobulin during the 2 weeks preceding the Screening Visit, or planned use during the study.
- Therapy with hematopoietic growth factors during the 4 weeks preceding the Screening Visit, or their planned use during the study.
- Therapy with alkylating chemotherapy drugs during the 8 weeks preceding the Screening Visit, or their planned use during the study.
- Use of other medicines listed in section 5.3.3. of this study protocol.
- Participation in a clinical trial of an investigational drug or investigational medical device within 4 weeks or 5 half-lives (whichever is longer) preceding the Screening Visit.
- Secondary immune thrombocytopenia in the following diseases: autoimmune thyroiditis, systemic lupus erythematosus (SLE), antiphospholipid syndrome (APLS), lymphoproliferative diseases, drug-mediated, viral origin (herpes viruses, HIV, chronic viral hepatitis).
- Hereditary thrombocytopenia.
- Diseases of the hematopoietic system accompanied by thrombocytopenia (for example, acute leukemia, aplastic anemia, myelodysplastic syndrome, lymphoproliferative diseases).
- Metastatic bone marrow lesions.
- Uncontrolled concomitant diseases of internal organs.
- Arterial thrombosis (for example, myocardial infarction, acute cerebrovascular accident) within 1 year preceding the Screening Visit.
- History of venous thrombosis.
- High risk of venous thrombosis and thromboembolism, defined as the presence of at least three of the following risk factors:
- diabetes;
- smoking;
- use of combined oral contraceptives or menopausal hormone therapy;
- positive titer of antiphospholipid antibodies;
- hypercholesterolemia (>240 mg/dl or >13 mmol/l);
- hypertriglyceridemia;
- arterial hypertension requiring therapy.
- HIV infection.
- Viral hepatitis B or C.
- Oncological and/or oncohematological disease beyond the stage of complete 5-year remission at the Screening Visit.
- Major surgery ("major surgery") within 8 weeks preceding the Screening Visit, or incomplete recovery from surgery at the Screening Visit.
- Pregnancy or lactation in women.
- Hospitalization for any reason planned during the patient's participation in the study.
- A history of mental disorders that do not allow you to adequately assess your behavior and follow the conditions of the study protocol.
- Alcoholism. Alcoholism or consumption of alcohol in quantities exceeding for men: 14 units. per week (on average); for women: 7 units. per week (on average).
Источник: ClinicalTrials.gov, NCT06497036 · запись обновлена в реестре 11 июля 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (5)
- Proportion of subjects with platelet response — 10 weeks
- Number of adverse events (AEs) — 10 weeks
- Proportion of subjects experiencing AEs, — 10 weeks
- Proportion subjects with a immune response to romiplostim — 26 weeks
- Proportion subjects with a immune response to endogenous thrombopoietin — 26 weeks
Цель исследования
The goal of this clinical trial is to demonstrate equivalent efficacy and comparable safety of the drug GP40141 (GEROPHARM, Russia) in comparison with the drug Nplate® (Amgen, the Netherlands). the main questions are
1. Assess the effectiveness of GP40141 in comparison with Nplate®.
2. Assess the immunogenicity of GP40141 in comparison with the drug Nplate®.
3. Assess the safety of GP40141 in comparison with the drug Nplate®.
4. Assess the safety of changing romiplostim and eltrombopag to GP40141.
5. Assess the pharmacokinetic parameters of the study drugs in patients with primary immune thrombocytopenia.
Participants divided into 2 cohorts (naïve or treated with a thrombopoietin receptor agonist) will receive romiplostim and platelet response, immune response and adverse reactions will be assessed.
Области и заболевания
Где проходит
12 центров в 11 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 185 от 04.04.2023 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06497036 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
clinmarket · № 7143 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.